Cellectis (CLLS) Cash & Equivalents (2014 - 2026)

Cellectis' Cash & Equivalents history runs 13 years deep, the most recent figure standing at $34.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 75.68% year-over-year to $34.8 million; the TTM figure through Mar 2026 stood at $34.8 million (down 75.68% YoY), while the FY2025 annual figure was $61.5 million, down 57.05% from the prior year.
• Cash & Equivalents was $34.8 million for Q1 2026 at Cellectis, down from $61.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $185.6 million in Q2 2022 to a low of $34.8 million in Q1 2026.
• Historically, Cash & Equivalents has averaged $114.9 million across 5 years, with a median of $136.7 million in 2023.
• The sharpest annual moves came in 2024 and 2026: Cash & Equivalents surged 59.89% in 2024, then tumbled 75.68% in 2026.
• A 5-year view of Cash & Equivalents shows it stood at $93.2 million in 2022, then soared by 46.66% to $136.7 million in 2023, then gained by 4.79% to $143.3 million in 2024, then slumped by 57.05% to $61.5 million in 2025, then plunged by 43.38% to $34.8 million in 2026.
• The last three Cash & Equivalents figures came in at $34.8 million (Q1 2026), $61.5 million (Q4 2025), and $52.2 million (Q3 2025), per Business Quant data.